Department of Neurology, Xi'an No.1 Hospital, The First Affiliated Hospital of Northwest University, Xi'an, 710002, China.
Department of Epidemiology and Biostatistics, School of Public Health of Xi'an Jiaotong University Health Science Center, Xi'an, 71006, China.
BMC Geriatr. 2023 Jul 5;23(1):410. doi: 10.1186/s12877-023-04102-x.
Few studies have explored the prognostic role of nontraditional lipid-related indicators in non-disabling ischemic cerebrovascular events (NICE). In this study, we aimed to investigate the relationship between the ratio of non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol (non-HDL-C/HDL-C) and the1-year risk of recurrent stroke in patients with NICE.
Total cholesterol (TC), HDL-C, and patient information were collected at admission. Recurrent stroke events were followed up 3, 6, and 12 months after onset. Non-HDL-C levels were calculated by subtracting HDL-C from TC. The non-HDL-C/HDL-C ratio was treated as a continuous variable and in quartiles (Q1-Q4). Stratified multivariate Cox regression was used to investigate the relationship between the non-HDL-C/HDL-C ratio and the 1-year risk of recurrent stroke in patients with NICE.
Overall, 1,659 patients with NICE were enrolled. For each unit increase in the non-HDL-C/HDL-C ratio, the 1-year risk of recurrent stroke in patients aged ≥ 65 years (older patients) with NICE increased by 64% in the adjusted model (hazard ratio [HR]: 1.64, 95%confidence interval [CI]:1.18-2.27, P = 0.003), and the HRs were 3.21 and 4.24 times higher in the Q3 and Q4 groups than that in the Q1 group, which was considered to be the reference (adjusted model Q3: HR: 3.21, 95%CI: 1.05-9.83, P = 0.041; adjusted model Q4: HR: 4.24, 95%CI: 1.30-13.85, P = 0.017). However, there was no significant difference in patients younger than 65 years. Both curve fitting and Kaplan-Meier cumulative risk analysis showed that an elevated non-HDL-C/HDL-C ratio significantly increased the 1-year risk of recurrent stroke in older patients with NICE. The optimal range for the non-HDL-C/HDL-C ratio should be no higher than the Q2 group (2.256-2.939). Stratified Cox regression analysis showed that these results tended to be stable for different comorbidities (all P for interaction > 0.05).
Elevated non-HDL-C/HDL-C ratios significantly increased the 1-year risk of recurrent stroke in older patients with NICE. Therefore, clinicians need to pay more attention to this indicator when managing older patients with NICE.
鲜有研究探讨非传统脂质相关指标在非致残性缺血性脑血管事件(NICE)中的预后作用。本研究旨在探讨非高密度脂蛋白胆固醇与高密度脂蛋白胆固醇比值(non-HDL-C/HDL-C)与 NICE 患者复发性卒中 1 年风险之间的关系。
入院时收集总胆固醇(TC)、高密度脂蛋白胆固醇(HDL-C)和患者信息。发病后 3、6 和 12 个月进行复发性卒中事件随访。通过从 TC 中减去 HDL-C 计算非 HDL-C 水平。non-HDL-C/HDL-C 比值被视为连续变量并分为四等分(Q1-Q4)。采用分层多变量 Cox 回归分析探讨 NICE 患者 non-HDL-C/HDL-C 比值与复发性卒中 1 年风险之间的关系。
共纳入 1659 例 NICE 患者。对于年龄≥65 岁(老年患者)的 NICE 患者,non-HDL-C/HDL-C 比值每增加 1 个单位,其复发性卒中 1 年风险在调整模型中增加 64%(风险比 [HR]:1.64,95%置信区间 [CI]:1.18-2.27,P=0.003),Q3 和 Q4 组的 HR 分别是 Q1 组的 3.21 和 4.24 倍(调整模型 Q3:HR:3.21,95%CI:1.05-9.83,P=0.041;调整模型 Q4:HR:4.24,95%CI:1.30-13.85,P=0.017)。然而,年龄小于 65 岁的患者无显著差异。曲线拟合和 Kaplan-Meier 累积风险分析均表明,non-HDL-C/HDL-C 比值升高显著增加了老年 NICE 患者的复发性卒中 1 年风险。non-HDL-C/HDL-C 比值的最佳范围应不高于 Q2 组(2.256-2.939)。分层 Cox 回归分析显示,对于不同的合并症,这些结果趋于稳定(所有交互 P 值均大于 0.05)。
non-HDL-C/HDL-C 比值升高显著增加了老年 NICE 患者的复发性卒中 1 年风险。因此,临床医生在管理老年 NICE 患者时需要更加关注这一指标。